RxDoctor Payments DataLook up a doctor →

Hudman Hoo, MD

Critical Care Medicine · St Petersburg, FLNPI 1396730339

Payments from drug & device makers

$190,817in general payments, 2019–2025

Across 521 payments — averaging $366.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$80K
  • Genentech, Inc.$54K
  • Insmed, Inc.$39K
  • Chiesi USA, Inc.$7K
  • Sanofi$2K
  • Viiv Healthcare Company$2K
  • plus $7K from 44 others

What the payments were for

  • Consulting fees$1,7903%
  • Speaking & faculty fees$39,70077%
  • Food & beverage$9,69619%
  • Education$2200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$190,817 in reported general payments places this provider in the 95th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$190,099
Medicare patients
474
Services billed
1,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat33$449,978
Trelegy ElliptaFluticasone/Umeclidin/Vilanter235$249,737
ZemairaAlpha-1-Proteinase Inhibitor12$98,810
Dupixent PenDupilumab12$53,123
Advair HfaFluticasone Propion/Salmeterol24$20,447
Breo ElliptaFluticasone/Vilanterol32$20,052
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$19,908
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$15,545
Spiriva RespimatTiotropium Bromide16$11,166
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$10,022
BreynaBudesonide/Formoterol Fumarate35$9,526
SymbicortBudesonide/Formoterol Fumarate21$9,474
Albuterol Sulfate HfaAlbuterol Sulfate127$4,043
Wixela InhubFluticasone Propion/Salmeterol18$1,877
Ventolin HfaAlbuterol Sulfate16$1,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$318$449,97833 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$80,142$289,697288 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,153$25,01939 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$794$21,18930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 618 critical care medicine providers in Florida.

Other critical care medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →